Collegium Pharmaceutical, Inc. Accrued Bonuses, Current
Collegium Pharmaceutical, Inc. (COLL) had Accrued Bonuses, Current of $4.10 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedBonusesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Bonuses, Current $4.10M.
- 2026-03-31: Accrued Bonuses, Current $2.20M.
- 2025-12-31: Accrued Bonuses, Current $9.17M.
- 2025-09-30: Accrued Bonuses, Current $5.19M.
| Period end | Accrued Bonuses, Current |
|---|---|
| 2026-06-30 | $4.10M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $9.17M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $5.19M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $3.28M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.44M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $8.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $7.40M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.48M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.41M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $4.99M 10-K · filed 2025-02-27 |
| 2023-09-30 | $4.10M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $2.67M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.33M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $6.35M 10-K · filed 2024-02-22 |
| 2022-09-30 | $3.42M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $2.40M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.36M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $2.63M 10-K · filed 2023-02-23 |
| 2021-09-30 | $2.92M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.86M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.01M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $4.57M 10-K · filed 2022-02-24 |
| 2020-09-30 | $3.41M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.33M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.20M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $4.05M 10-K · filed 2021-02-25 |
| 2019-09-30 | $3.29M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $2.01M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $1.01M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $4.29M 10-K · filed 2020-02-27 |
| 2018-09-30 | $2.72M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $1.83M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $1.45M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $2.94M 10-K · filed 2019-02-27 |
| 2017-09-30 | $2.09M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $1.40M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $730.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $2.21M 10-K · filed 2018-03-07 |
| 2016-09-30 | $2.89M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $2.28M 10-Q · filed 2016-08-11 |
| 2016-03-31 | $828.00K 10-Q · filed 2016-05-11 |
| 2015-12-31 | $1.47M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |